Evolving Treatment of Advanced Colon Cancer

被引:108
作者
Segal, Neil H. [1 ]
Saltz, Leonard B. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY 10065 USA
来源
ANNUAL REVIEW OF MEDICINE | 2009年 / 60卷
关键词
combination strategies; targeted agents; sequencing; planned interruption; METASTATIC COLORECTAL-CANCER; RANDOMIZED PHASE-II; FLUOROURACIL PLUS LEUCOVORIN; GROWTH-FACTOR RECEPTOR; QUALITY-OF-LIFE; 1ST-LINE TREATMENT; CONTROLLED-TRIAL; COMBINATION CHEMOTHERAPY; ORAL FLUOROPYRIMIDINES; CONTINUOUS-INFUSION;
D O I
10.1146/annurev.med.60.041807.132435
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Colorectal cancer is a common malignancy worldwide. Despite significant developments in the treatment of this disease, it still causes considerable morbidity and mortality. Recent advances include both newer cytotoxic chemotherapies and novel biologic agents. Although overall progress has been more modest than had been hoped, substantial benefits have been achieved for some patients, and the number of treatment options has substantially increased. Perhaps most importantly, treatment regimens can now be selected and tailored toward the individual patient following an informed discussion between the patient awl the treating oncologist. We present in detail these recent advances and provide some insight into several promising future strategies.
引用
收藏
页码:207 / 219
页数:13
相关论文
共 59 条
[1]  
Amado RG, 2008, AM SOC CLIN ONC GAST
[2]  
Au H, 2007, J CLIN ONCOL, V25
[3]  
BERRY SR, 2008, AM SOC CLIN ONC GAST
[4]  
Bouché O, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2005.04.7118
[5]  
CASSIDY J, 2008, AM SOC CLIN ONC GAST
[6]   Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810
[7]   Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale [J].
Colucci, G ;
Gebbia, V ;
Paoletti, G ;
Giuliani, F ;
Caruso, M ;
Gebbia, N ;
Carteni, G ;
Agostara, B ;
Pezzella, G ;
Manzione, L ;
Borsellino, N ;
Misino, A ;
Romito, S ;
Durini, E ;
Cordio, S ;
Di Seri, M ;
Lopez, M ;
Maiello, E .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4866-4875
[8]   Irinotecan is an active agent in untreated patients with metastatic colorectal cancer [J].
Conti, JA ;
Kemeny, NE ;
Saltz, LB ;
Huang, Y ;
Tong, WP ;
Chou, TC ;
Sun, M ;
Pulliam, S ;
Gonzalez, C .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :709-715
[9]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[10]   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].
Cunningham, D ;
Pyrhönen, S ;
James, RD ;
Punt, CJA ;
Hickish, TF ;
Heikkila, R ;
Johannesen, TB ;
Starkhammar, H ;
Topham, CA ;
Awad, L ;
Jacques, C ;
Herait, P .
LANCET, 1998, 352 (9138) :1413-1418